Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia

Blood. 2024 Sep 19;144(12):1343-1347. doi: 10.1182/blood.2023023400.

Abstract

We report on the antileukemic activity of homoharringtonine (HHT) in T-cell acute lymphoblastic leukemia (T-ALL). We showed that HHT inhibited the NOTCH/MYC pathway and induced significantly longer survival in mouse and patient-derived T-ALL xenograft models, supporting HHT as a promising agent for T-ALL.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Harringtonines* / pharmacology
  • Harringtonines* / therapeutic use
  • Homoharringtonine* / pharmacology
  • Homoharringtonine* / therapeutic use
  • Humans
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / metabolism
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / pathology
  • Proto-Oncogene Proteins c-myc* / genetics
  • Proto-Oncogene Proteins c-myc* / metabolism
  • Receptors, Notch* / antagonists & inhibitors
  • Receptors, Notch* / metabolism
  • Signal Transduction* / drug effects
  • Xenograft Model Antitumor Assays*

Substances

  • Homoharringtonine
  • Harringtonines
  • Receptors, Notch
  • Proto-Oncogene Proteins c-myc
  • MYC protein, human